64 related articles for article (PubMed ID: 16085341)
1. DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.
Horiuchi R; Akahata W; Kuwata T; Enose Y; Ido E; Suzuki H; Miyake A; Saito N; Ibuki K; Goto T; Miura T; Hayami M
Vaccine; 2006 Apr; 24(17):3677-85. PubMed ID: 16085341
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles.
Akahata W; Ido E; Akiyama H; Uesaka H; Enose Y; Horiuchi R; Kuwata T; Goto T; Takahashi H; Hayami M
J Gen Virol; 2003 Aug; 84(Pt 8):2237-2244. PubMed ID: 12867656
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
5. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
6. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
[TBL] [Abstract][Full Text] [Related]
7. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
8. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
9. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR
Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943
[TBL] [Abstract][Full Text] [Related]
10. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
12. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques.
Shimizu Y; Inaba K; Kaneyasu K; Ibuki K; Himeno A; Okoba M; Goto Y; Hayami M; Miura T; Haga T
Virology; 2007 Apr; 361(1):68-79. PubMed ID: 17157892
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
[TBL] [Abstract][Full Text] [Related]
17. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
18. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.
Amara RR; Ibegbu C; Villinger F; Montefiori DC; Sharma S; Nigam P; Xu Y; McClure HM; Robinson HL
Virology; 2005 Dec; 343(2):246-55. PubMed ID: 16185742
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.
Suh YS; Park KS; Sauermann U; Kim KS; Ahn SS; Franz M; Schulte R; Wilfingseder D; Stoiber H; Uberla K; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2008 Dec; 26(51):6690-8. PubMed ID: 18694796
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
